Report Detail
COVID-19 Impact on Global Gene Therapy in Oncology Market Size, Status and Forecast 2020-2026
- RnM3985474 |
- 03 June, 2020 |
- Global |
- 125 Pages |
- QYResearch |
- Other
Gene therapy refers to any procedure that aims to treat or alleviate a disease by genetically modifying the cell of a patient.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Gene Therapy in Oncology market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Gene Therapy in Oncology industry.
Based on our recent survey, we have several different scenarios about the Gene Therapy in Oncology YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Gene Therapy in Oncology will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Therapy in Oncology market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Therapy in Oncology market in terms of revenue.
Players, stakeholders, and other participants in the global Gene Therapy in Oncology market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Gene Therapy in Oncology market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Gene Therapy in Oncology market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy in Oncology market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy in Oncology market.
The following players are covered in this report:
Bristol-Myers Squibb
Cold Genesys
Advantagene
Amgen
AstraZeneca
Bio-Path Holdings
CRISPR Therapeutics
Editas Medicine
Geron Corp
Idera Pharmaceuticals
Intellia Therapeutics
Johnson & Johnson
Marsala Biotech
Merck
Mologen AG
Oncolytics Biotech
Oncosec
Oncotelic
Shenzhen SiBiono GeneTech
Sillajen Biotherapeutics
Tocagen
UniQure
Ziopharm Oncology
Gene Therapy in Oncology Breakdown Data by Type
Ex Vivo
In Vivo
Gene Therapy in Oncology Breakdown Data by Application
Hospitals
Diagnostics Centers
Research Institutes
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Gene Therapy in Oncology Revenue
- 1.4 Market Analysis by Type
- 1.4.1 Global Gene Therapy in Oncology Market Size Growth Rate by Type: 2020 VS 2026
- 1.4.2 Ex Vivo
- 1.4.3 In Vivo
- 1.5 Market by Application
- 1.5.1 Global Gene Therapy in Oncology Market Share by Application: 2020 VS 2026
- 1.5.2 Hospitals
- 1.5.3 Diagnostics Centers
- 1.5.4 Research Institutes
- 1.6 Coronavirus Disease 2019 (Covid-19): Gene Therapy in Oncology Industry Impact
- 1.6.1 How the Covid-19 is Affecting the Gene Therapy in Oncology Industry
- 1.6.1.1 Gene Therapy in Oncology Business Impact Assessment - Covid-19
- 1.6.1.2 Supply Chain Challenges
- 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
- 1.6.2 Market Trends and Gene Therapy in Oncology Potential Opportunities in the COVID-19 Landscape
- 1.6.3 Measures / Proposal against Covid-19
- 1.6.3.1 Government Measures to Combat Covid-19 Impact
- 1.6.3.2 Proposal for Gene Therapy in Oncology Players to Combat Covid-19 Impact
- 1.6.1 How the Covid-19 is Affecting the Gene Therapy in Oncology Industry
- 1.7 Study Objectives
- 1.8 Years Considered
2 Global Growth Trends by Regions
- 2.1 Gene Therapy in Oncology Market Perspective (2015-2026)
- 2.2 Gene Therapy in Oncology Growth Trends by Regions
- 2.2.1 Gene Therapy in Oncology Market Size by Regions: 2015 VS 2020 VS 2026
- 2.2.2 Gene Therapy in Oncology Historic Market Share by Regions (2015-2020)
- 2.2.3 Gene Therapy in Oncology Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Porter’s Five Forces Analysis
- 2.3.5 Gene Therapy in Oncology Market Growth Strategy
- 2.3.6 Primary Interviews with Key Gene Therapy in Oncology Players (Opinion Leaders)
3 Competition Landscape by Key Players
- 3.1 Global Top Gene Therapy in Oncology Players by Market Size
- 3.1.1 Global Top Gene Therapy in Oncology Players by Revenue (2015-2020)
- 3.1.2 Global Gene Therapy in Oncology Revenue Market Share by Players (2015-2020)
- 3.1.3 Global Gene Therapy in Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Gene Therapy in Oncology Market Concentration Ratio
- 3.2.1 Global Gene Therapy in Oncology Market Concentration Ratio (CR5 and HHI)
- 3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy in Oncology Revenue in 2019
- 3.3 Gene Therapy in Oncology Key Players Head office and Area Served
- 3.4 Key Players Gene Therapy in Oncology Product Solution and Service
- 3.5 Date of Enter into Gene Therapy in Oncology Market
- 3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
- 4.1 Global Gene Therapy in Oncology Historic Market Size by Type (2015-2020)
- 4.2 Global Gene Therapy in Oncology Forecasted Market Size by Type (2021-2026)
5 Gene Therapy in Oncology Breakdown Data by Application (2015-2026)
- 5.1 Global Gene Therapy in Oncology Market Size by Application (2015-2020)
- 5.2 Global Gene Therapy in Oncology Forecasted Market Size by Application (2021-2026)
6 North America
- 6.1 North America Gene Therapy in Oncology Market Size (2015-2020)
- 6.2 Gene Therapy in Oncology Key Players in North America (2019-2020)
- 6.3 North America Gene Therapy in Oncology Market Size by Type (2015-2020)
- 6.4 North America Gene Therapy in Oncology Market Size by Application (2015-2020)
7 Europe
- 7.1 Europe Gene Therapy in Oncology Market Size (2015-2020)
- 7.2 Gene Therapy in Oncology Key Players in Europe (2019-2020)
- 7.3 Europe Gene Therapy in Oncology Market Size by Type (2015-2020)
- 7.4 Europe Gene Therapy in Oncology Market Size by Application (2015-2020)
8 China
- 8.1 China Gene Therapy in Oncology Market Size (2015-2020)
- 8.2 Gene Therapy in Oncology Key Players in China (2019-2020)
- 8.3 China Gene Therapy in Oncology Market Size by Type (2015-2020)
- 8.4 China Gene Therapy in Oncology Market Size by Application (2015-2020)
9 Japan
- 9.1 Japan Gene Therapy in Oncology Market Size (2015-2020)
- 9.2 Gene Therapy in Oncology Key Players in Japan (2019-2020)
- 9.3 Japan Gene Therapy in Oncology Market Size by Type (2015-2020)
- 9.4 Japan Gene Therapy in Oncology Market Size by Application (2015-2020)
10 Southeast Asia
- 10.1 Southeast Asia Gene Therapy in Oncology Market Size (2015-2020)
- 10.2 Gene Therapy in Oncology Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Gene Therapy in Oncology Market Size by Type (2015-2020)
- 10.4 Southeast Asia Gene Therapy in Oncology Market Size by Application (2015-2020)
11 India
- 11.1 India Gene Therapy in Oncology Market Size (2015-2020)
- 11.2 Gene Therapy in Oncology Key Players in India (2019-2020)
- 11.3 India Gene Therapy in Oncology Market Size by Type (2015-2020)
- 11.4 India Gene Therapy in Oncology Market Size by Application (2015-2020)
12 Central & South America
- 12.1 Central & South America Gene Therapy in Oncology Market Size (2015-2020)
- 12.2 Gene Therapy in Oncology Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Gene Therapy in Oncology Market Size by Type (2015-2020)
- 12.4 Central & South America Gene Therapy in Oncology Market Size by Application (2015-2020)
13 Key Players Profiles
- 13.1 Bristol-Myers Squibb
- 13.1.1 Bristol-Myers Squibb Company Details
- 13.1.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
- 13.1.3 Bristol-Myers Squibb Gene Therapy in Oncology Introduction
- 13.1.4 Bristol-Myers Squibb Revenue in Gene Therapy in Oncology Business (2015-2020))
- 13.1.5 Bristol-Myers Squibb Recent Development
- 13.2 Cold Genesys
- 13.2.1 Cold Genesys Company Details
- 13.2.2 Cold Genesys Business Overview and Its Total Revenue
- 13.2.3 Cold Genesys Gene Therapy in Oncology Introduction
- 13.2.4 Cold Genesys Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.2.5 Cold Genesys Recent Development
- 13.3 Advantagene
- 13.3.1 Advantagene Company Details
- 13.3.2 Advantagene Business Overview and Its Total Revenue
- 13.3.3 Advantagene Gene Therapy in Oncology Introduction
- 13.3.4 Advantagene Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.3.5 Advantagene Recent Development
- 13.4 Amgen
- 13.4.1 Amgen Company Details
- 13.4.2 Amgen Business Overview and Its Total Revenue
- 13.4.3 Amgen Gene Therapy in Oncology Introduction
- 13.4.4 Amgen Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.4.5 Amgen Recent Development
- 13.5 AstraZeneca
- 13.5.1 AstraZeneca Company Details
- 13.5.2 AstraZeneca Business Overview and Its Total Revenue
- 13.5.3 AstraZeneca Gene Therapy in Oncology Introduction
- 13.5.4 AstraZeneca Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.5.5 AstraZeneca Recent Development
- 13.6 Bio-Path Holdings
- 13.6.1 Bio-Path Holdings Company Details
- 13.6.2 Bio-Path Holdings Business Overview and Its Total Revenue
- 13.6.3 Bio-Path Holdings Gene Therapy in Oncology Introduction
- 13.6.4 Bio-Path Holdings Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.6.5 Bio-Path Holdings Recent Development
- 13.7 CRISPR Therapeutics
- 13.7.1 CRISPR Therapeutics Company Details
- 13.7.2 CRISPR Therapeutics Business Overview and Its Total Revenue
- 13.7.3 CRISPR Therapeutics Gene Therapy in Oncology Introduction
- 13.7.4 CRISPR Therapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.7.5 CRISPR Therapeutics Recent Development
- 13.8 Editas Medicine
- 13.8.1 Editas Medicine Company Details
- 13.8.2 Editas Medicine Business Overview and Its Total Revenue
- 13.8.3 Editas Medicine Gene Therapy in Oncology Introduction
- 13.8.4 Editas Medicine Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.8.5 Editas Medicine Recent Development
- 13.9 Geron Corp
- 13.9.1 Geron Corp Company Details
- 13.9.2 Geron Corp Business Overview and Its Total Revenue
- 13.9.3 Geron Corp Gene Therapy in Oncology Introduction
- 13.9.4 Geron Corp Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.9.5 Geron Corp Recent Development
- 13.10 Idera Pharmaceuticals
- 13.10.1 Idera Pharmaceuticals Company Details
- 13.10.2 Idera Pharmaceuticals Business Overview and Its Total Revenue
- 13.10.3 Idera Pharmaceuticals Gene Therapy in Oncology Introduction
- 13.10.4 Idera Pharmaceuticals Revenue in Gene Therapy in Oncology Business (2015-2020)
- 13.10.5 Idera Pharmaceuticals Recent Development
- 13.11 Intellia Therapeutics
- 10.11.1 Intellia Therapeutics Company Details
- 10.11.2 Intellia Therapeutics Business Overview and Its Total Revenue
- 10.11.3 Intellia Therapeutics Gene Therapy in Oncology Introduction
- 10.11.4 Intellia Therapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.11.5 Intellia Therapeutics Recent Development
- 13.12 Johnson & Johnson
- 10.12.1 Johnson & Johnson Company Details
- 10.12.2 Johnson & Johnson Business Overview and Its Total Revenue
- 10.12.3 Johnson & Johnson Gene Therapy in Oncology Introduction
- 10.12.4 Johnson & Johnson Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.12.5 Johnson & Johnson Recent Development
- 13.13 Marsala Biotech
- 10.13.1 Marsala Biotech Company Details
- 10.13.2 Marsala Biotech Business Overview and Its Total Revenue
- 10.13.3 Marsala Biotech Gene Therapy in Oncology Introduction
- 10.13.4 Marsala Biotech Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.13.5 Marsala Biotech Recent Development
- 13.14 Merck
- 10.14.1 Merck Company Details
- 10.14.2 Merck Business Overview and Its Total Revenue
- 10.14.3 Merck Gene Therapy in Oncology Introduction
- 10.14.4 Merck Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.14.5 Merck Recent Development
- 13.15 Mologen AG
- 10.15.1 Mologen AG Company Details
- 10.15.2 Mologen AG Business Overview and Its Total Revenue
- 10.15.3 Mologen AG Gene Therapy in Oncology Introduction
- 10.15.4 Mologen AG Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.15.5 Mologen AG Recent Development
- 13.16 Oncolytics Biotech
- 10.16.1 Oncolytics Biotech Company Details
- 10.16.2 Oncolytics Biotech Business Overview and Its Total Revenue
- 10.16.3 Oncolytics Biotech Gene Therapy in Oncology Introduction
- 10.16.4 Oncolytics Biotech Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.16.5 Oncolytics Biotech Recent Development
- 13.17 Oncosec
- 10.17.1 Oncosec Company Details
- 10.17.2 Oncosec Business Overview and Its Total Revenue
- 10.17.3 Oncosec Gene Therapy in Oncology Introduction
- 10.17.4 Oncosec Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.17.5 Oncosec Recent Development
- 13.18 Oncotelic
- 10.18.1 Oncotelic Company Details
- 10.18.2 Oncotelic Business Overview and Its Total Revenue
- 10.18.3 Oncotelic Gene Therapy in Oncology Introduction
- 10.18.4 Oncotelic Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.18.5 Oncotelic Recent Development
- 13.19 Shenzhen SiBiono GeneTech
- 10.19.1 Shenzhen SiBiono GeneTech Company Details
- 10.19.2 Shenzhen SiBiono GeneTech Business Overview and Its Total Revenue
- 10.19.3 Shenzhen SiBiono GeneTech Gene Therapy in Oncology Introduction
- 10.19.4 Shenzhen SiBiono GeneTech Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.19.5 Shenzhen SiBiono GeneTech Recent Development
- 13.20 Sillajen Biotherapeutics
- 10.20.1 Sillajen Biotherapeutics Company Details
- 10.20.2 Sillajen Biotherapeutics Business Overview and Its Total Revenue
- 10.20.3 Sillajen Biotherapeutics Gene Therapy in Oncology Introduction
- 10.20.4 Sillajen Biotherapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.20.5 Sillajen Biotherapeutics Recent Development
- 13.21 Tocagen
- 10.21.1 Tocagen Company Details
- 10.21.2 Tocagen Business Overview and Its Total Revenue
- 10.21.3 Tocagen Gene Therapy in Oncology Introduction
- 10.21.4 Tocagen Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.21.5 Tocagen Recent Development
- 13.22 UniQure
- 10.22.1 UniQure Company Details
- 10.22.2 UniQure Business Overview and Its Total Revenue
- 10.22.3 UniQure Gene Therapy in Oncology Introduction
- 10.22.4 UniQure Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.22.5 UniQure Recent Development
- 13.23 Ziopharm Oncology
- 10.23.1 Ziopharm Oncology Company Details
- 10.23.2 Ziopharm Oncology Business Overview and Its Total Revenue
- 10.23.3 Ziopharm Oncology Gene Therapy in Oncology Introduction
- 10.23.4 Ziopharm Oncology Revenue in Gene Therapy in Oncology Business (2015-2020)
- 10.23.5 Ziopharm Oncology Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.2 Data Source
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on COVID-19 Impact on Global Gene Therapy in Oncology. Industry analysis & Market Report on COVID-19 Impact on Global Gene Therapy in Oncology is a syndicated market report, published as COVID-19 Impact on Global Gene Therapy in Oncology Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of COVID-19 Impact on Global Gene Therapy in Oncology market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
